Linked Life Data

15264106

Source:http://linkedlifedata.com/resource/pubmed/id/15264106

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2004-7-20
pubmed:abstractText
Antibodies develop to varying degrees during treatment with human proteins, including insulin, growth hormone, granulocyte-macrophage colony-stimulating factor, factor VIII, erythropoietin, and interferons. These antibodies may reduce the clinical efficacy of these agents by blocking or neutralizing their biologic activity and may have other biologic effects. For example, antibodies develop in 20 % to 40% of patients with severe hemophilia treated with human factor VIII; the presence of these antibodies can result in tolerance to the clotting effects of this agent. Similarly, a proportion of patients treated with interferon alpha develop antibodies, which inhibit its therapeutic effects. Therefore, it is important to test for neutralizing antibodies during treatment with these agents, particularly in patients who are unresponsive to treatment or have breakthrough disease. This article reviews the incidence and clinical impact of antibodies that develop in response to some of the commonly used protein therapeutic agents.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0340-5354
pubmed:author
pubmed:issnType
Print
pubmed:volume
251 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
II4-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Immunogenicity of recombinant human proteins: causes and consequences.
pubmed:affiliation
Central Laboratory Animal Institute and Department of Innovation Studies, Utrecht University, Utrecht, The Netherlands. huubs@xs4all.nl
pubmed:publicationType
Journal Article, Review